Literature DB >> 15506661

Natural history of initially mild chronic hepatitis C.

A Alberti1, L Benvegnù, S Boccato, A Ferrari, G Sebastiani.   

Abstract

The hepatitis C virus is a leading cause of chronic liver disease, cirrhosis and hepatocellular carcinoma in western countries. Chronic hepatitis C is highly heterogeneous and many patients present with a mild form of liver disease. Population-based studies have indeed demonstrated that around 50% of hepatitis C virus carriers have persistently normal ALT and two-third have mild histological liver lesions. Studies on the natural history of initially mild chronic disease indicate that the short-term outcome is always benign. However, progression of liver fibrosis can be observed at long-term (>5-7 years) follow-up, particularly in those cases who have elevated and/or fluctuating transaminase levels. Observational prospective studies and outcome modelling projections indicate that the risk of liver disease progression towards severe fibrosis/cirrhosis is minimal at 10-15 years in hepatitis C virus carriers with persistently normal ALT, around 5-10% in patients with elevated ALT and F0 (no fibrosis) in the initial biopsy but >30-40% in chronic carriers with elevated ALT and F1 (portal fibrosis) in the initial biopsy. Cofactors like age at infection, alcohol, coinfections and liver steatosis accelerate disease progression. On the basis of these findings, patients with initially mild chronic hepatitis C and elevated ALT should be proposed for antiviral therapy in the absence of contraindications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15506661     DOI: 10.1016/j.dld.2004.06.011

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  9 in total

1.  Spontaneous clearance of hepatitis C virus in vertically infected children.

Authors:  Susan Farmand; Stefan Wirth; Helga Löffler; Tanja Woltering; Sybille Kenzel; Elke Lainka; Philipp Henneke
Journal:  Eur J Pediatr       Date:  2011-07-07       Impact factor: 3.183

2.  Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels.

Authors:  Bryce D Smith; Anthony K Yartel
Journal:  Am J Prev Med       Date:  2014-09       Impact factor: 5.043

Review 3.  Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.

Authors:  Giada Sebastiani; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

4.  Disease progression in Chinese patients with hepatitis C virus RNA-positive infection via blood transfusion.

Authors:  Yan-Feng Pan; Yan Zheng; Tao Qin; Lei Feng; Qian Zhang; Xiao-Gong Ping; Yan-Ting Pan; Xiao-Ping Wang; Li Bai; Hua-Hua Li
Journal:  Exp Ther Med       Date:  2016-10-11       Impact factor: 2.447

5.  Factors associated with seroprevalence of hepatitis C among dentists at a large Brazilian city.

Authors:  Vera Lúcia S Resende; Mauro Henrique G Abreu; Saul M Paiva; Rosângela Teixeira; Isabela A Pordeus
Journal:  Virol J       Date:  2009-12-23       Impact factor: 4.099

Review 6.  Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma.

Authors:  Lydia Giannitrapani; Maurizio Soresi; Daniele Balasus; Anna Licata; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

Review 7.  Natural History of Hepatitis C.

Authors:  Shilpa Lingala; Marc G Ghany
Journal:  Gastroenterol Clin North Am       Date:  2015-08-25       Impact factor: 3.806

8.  Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels.

Authors:  Hirofumi Uto; Seiich Mawatari; Kotaro Kumagai; Akio Ido; Hirohito Tsubouchi
Journal:  Hepat Mon       Date:  2012-02-29       Impact factor: 0.660

9.  Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time?

Authors:  Omar S Khokhar; James H Lewis
Journal:  Dig Dis Sci       Date:  2007-03-15       Impact factor: 3.487

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.